Andrew T. Parsa, MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.

A patient does not have to go through leukapheresis, nor receive additional cytokines such as GM-CSF, a common approach for many types of vaccines for brain tumor patients. As a part of standard of care, a patient undergoes surgical resection. That resected tissue is used to make the vaccine. In a majority of cases, patients who have a recurrent glioblastoma can have the vaccine made from surgical resection without an issue.

A physician will administer as many doses as a patient can tolerate with regard to the amount of vaccine, up to six, Parsa says.

Videos

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme. 

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme. This ongoing phase II study, sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute, was designed so that patients who have recurrent glioblastoma undergo surgical resection and have confirmation of their diagnosis. Then, the resected tissue is converted into the vaccine, which is held by researchers.

Patients in the trial are randomized to one of three arms: bevacizumab alone, the current standard of care in this disease, bevacizumab in combination with the vaccine, or the vaccine followed by bevacizumab. The study looks to answer the question of whether prophage G-200 can facilitate long term overall survival.

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Andrew T. Parsa, MD, PhD

Articles

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma